The Antiangiogenic and Antitumor Effects of Scoparasin B in Non-Small-Cell Lung Cancer

Area of Science:

• Marine natural products
• Cancer biology
• Molecular oncology

Background:

• Angiogenesis and vasculogenic mimicry (VM) are critical for non-small-cell lung cancer (NSCLC) progression and metastasis.
• Current therapies targeting only endothelial cell-mediated angiogenesis often fail due to tumor-cell-mediated VM, leading to recurrence.
• Natural products offer a promising avenue for discovering novel inhibitors of both angiogenesis and VM.

Purpose of the Study:

• To investigate the anti-angiogenic and anti-VM effects of scoparasin B, a pimarane diterpene from marine fungus Eutypella sp. F0219.
• To evaluate the efficacy of scoparasin B in inhibiting NSCLC growth, angiogenesis, and VM in vivo.
• To elucidate the molecular mechanism underlying scoparasin B's action on tumor angiogenesis and VM.

Main Methods:

• In vitro and ex vivo assays to assess inhibition of angiogenesis and VM.
• NCI-H1299 xenograft mouse model to evaluate tumor growth, angiogenesis, and VM inhibition.
• Western blot analysis to measure VEGF-A levels and assess VEGFR2 signaling pathway activation.

Main Results:

• Scoparasin B demonstrated significant inhibition of angiogenesis and VM in vitro and ex vivo.
• In vivo, scoparasin B markedly reduced tumor growth, angiogenesis, and VM in the NSCLC xenograft model.
• Scoparasin B suppressed tumor angiogenesis and VM by decreasing VEGF-A levels and inhibiting the VEGF-A/VEGFR2 signaling pathway.

Conclusions:

• Scoparasin B effectively inhibits tumor angiogenesis, VM, and NSCLC growth.
• The mechanism involves the downregulation of VEGF-A and suppression of the VEGF-A/VEGFR2 pathway.
• Scoparasin B represents a potential novel therapeutic agent for NSCLC and highlights the value of marine natural products in drug discovery.